Lexaria Bioscience Corp (LEXX)
2.29
-0.08
(-3.38%)
USD |
NASDAQ |
Dec 27, 16:00
2.26
-0.03
(-1.31%)
After-Hours: 20:00
Lexaria Bioscience Cash from Financing (Quarterly): 0.00 for Aug. 31, 2024
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Aurinia Pharmaceuticals Inc | -2.722M |
| Edesa Biotech Inc | -0.0314M |
| Xenon Pharmaceuticals Inc | 0.00 |
| ESSA Pharma Inc | 0.0597M |
| ImmunoPrecise Antibodies Ltd | 1.522M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.892M |
| Cash from Investing (Quarterly) | -0.0696M |
| Free Cash Flow | -5.148M |
| Free Cash Flow Per Share (Quarterly) | -0.1248 |
| Free Cash Flow to Equity (Quarterly) | -1.961M |
| Free Cash Flow Yield | -18.21% |